Business
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
LOS ALTOS, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing
About this update from Renovorx, Inc.
[{"type":"text","content":" LOS ALTOS, Calif.--(BUSINESS WIRE)--\nRenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA. Register here to access the live webcast.\n\n\nMr. Bagai will discuss recent Company milestones, including the research collaboration with Imugene (ASX: IMU), and highlights from RenovoRx’s open label pivotal Phase III TIGeR-PaC study. The TIGeR-PaC study is evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). Interim data demonstrates a 6-month overall survival benefit, 8-month delay in cancer progression, and 65% reduction in adverse effects over systemic (intravenous) chemotherapy. The data, presented at the recent 2023 ESMO World Congress on Gastrointestinal Cancer, drove the decision from the TIGeR-PaC Data Monitoring Committee (DMC) to continue this pivotal trial.\n\n\n43rd Annual Canaccord Genuity Growth Conference\nDate: August 10, 2023\nTime: 10:30 – 10:55 AM ET\nSpeaker: Shaun Bagai, CEO of RenovoRx\nLocation: Boston, Massachusetts\nWebcast: https://wsw.com/webcast/canaccord89/rnxt/2519572\n\n\nTo schedule a one-on-one investor meeting with RenovoRx’s management team, please contact a conference representative or KCSA Strategic Communications at [email protected].\n\n\nA webcast of the event will be available for a limited time in the Investors section of the Company’s website.\n\n\nAbout RenovoRx, Inc.\n\n\nRenovoRx is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical needs. The Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to bypass traditional systemic delivery methods and ensure precise therapeutic delivery to a target tissue, while minimizing a therapy’s systemic toxicities. RenovoRx’s unique approach to drug-delivery offers the potential for increased treatment safety, tolerance, and wider therapeutic windows. The Company’s lead product candidate, RenovoGem™ combines gemcitabine with the company’s patented delivery system and is regulated by ...